MacroGenics Inc (MGNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MacroGenics Inc (MGNX) has a cash flow conversion efficiency ratio of 0.774x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($43.02 Million) by net assets ($55.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MacroGenics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how MacroGenics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MacroGenics Inc total liabilities for a breakdown of total debt and financial obligations.
MacroGenics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MacroGenics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gwangjushinseg
KO:037710
|
0.039x |
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
0.032x |
|
Sif Holding NV
AS:SIFG
|
0.147x |
|
Montauk Renewables Inc
NASDAQ:MNTK
|
0.049x |
|
Hengyuan Refining Company Bhd
KLSE:4324
|
0.281x |
|
Pyridam Farma Tbk
JK:PYFA
|
-0.213x |
|
PAMT CORP
NASDAQ:PAMT
|
-0.028x |
|
Siward Crystal Technology Co Ltd
TW:2484
|
0.029x |
Annual Cash Flow Conversion Efficiency for MacroGenics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of MacroGenics Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see MGNX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $55.59 Million | $-81.04 Million | -1.458x | -147.45% |
| 2024-12-31 | $116.06 Million | $-68.37 Million | -0.589x | -14.97% |
| 2023-12-31 | $152.61 Million | $-78.20 Million | -0.512x | +16.31% |
| 2022-12-31 | $142.01 Million | $-86.96 Million | -0.612x | -2.01% |
| 2021-12-31 | $239.62 Million | $-143.83 Million | -0.600x | -58.72% |
| 2020-12-31 | $295.88 Million | $-111.90 Million | -0.378x | +35.04% |
| 2019-12-31 | $230.63 Million | $-134.27 Million | -0.582x | +7.72% |
| 2018-12-31 | $242.88 Million | $-153.23 Million | -0.631x | -1410.61% |
| 2017-12-31 | $299.24 Million | $14.40 Million | 0.048x | +129.62% |
| 2016-12-31 | $268.75 Million | $-43.68 Million | -0.163x | -272.78% |
| 2015-12-31 | $313.34 Million | $-13.66 Million | -0.044x | +83.86% |
| 2014-12-31 | $121.29 Million | $-32.76 Million | -0.270x | -50.40% |
| 2013-12-31 | $78.91 Million | $-14.17 Million | -0.180x | -122.48% |
| 2012-12-31 | $-8.24 Million | $-6.58 Million | 0.799x | +306.75% |
| 2011-12-31 | $-17.48 Million | $6.76 Million | -0.386x | -- |
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tri… Read more